Select Page

Cancer Drug Pipeline Information for Patient Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained on this website is not a comprehensive list. While we make reasonable efforts to present current and accurate information on this website, this website could include inaccuracies or typographical errors. We do not guarantee and are not responsible for the quality, currency, propriety, accuracy, or reasonableness of any information on this website. Please contact info@canceraction.ca with any inquiries about the terms of use.

Brand NameGeneric NameManufacturerTumour SiteIndicationRoute of AdministrationInformation Source
MasivetmasitinibAB ScienceGastrointestinalRelapsed metastatic colorectal cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalMetastatic pancreatic cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, first-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceMelanomaMetastatic melanoma with JM mutation of c-KITOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, second-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGynecologyRelapsed advanced / metastatic epithelial ovarian cancer patients in second line refractory to first line platinum treatment or in third lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGenitourinaryMetastatic Castrate Resistant Prostate Cancer in first lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceLymphomaRelapsed or refractory peripheral T-cell lymphomaOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
VenclextavenetoclaxAbbVieLeukemiaChronic lymphocytic leukemia (CLL), relapsed-refractory and first lineOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaFollicular Lymphoma (FL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaDiffuse Large B-Cell Lymphoma (DLBCL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieMyelomaMultiple myelomaOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
veliparibAbbVieLungOvarian cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieBreastBreast cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieLungLung cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, third lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, first lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer,second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieGastrointestinalPancreatic cancerOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaMarginal zone lymphoma (MZL), relapsed/refractoryOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaDiffuse large B-cell lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaFollicular lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma treatment naïveIntravenoushttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
depatuxizumab mafodotinAbbVieNeurologicalGlioblastoma MultiformeIntravenoushttps://www.abbvie.com/our-science/pipeline/depatuxizumab-mafodotin.html
Imlygictalimogene laherparepvecAmgenMelanomaUnresected metastatic melanomaSubcutaneoushttp://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=talimogene+laherparepvec
XgevadenosumabAmgenOtherAdults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbiditySubcutaneoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
KyproliscarfilzomibAmgenMyelomaMultiple myeloma, in combination with chemotherapyIntravenoushttp://www.amgenpipeline.com/pipeline/
KyproliscarfilzomibAmgenLungSmall-cell lung cancerIntravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLeukemiaPhiladelphia Positive/BCR-ABL Positive Acute Lymphoblastic LeukemiaIntravenoushttp://www.amgenpipeline.com/pipeline/
encorafenibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with binimetinibOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
encorafenibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer in combination with binimetinib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
binimetinibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer, in combination with encorafenib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
binimetinibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with encorafenibOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
IMAB362Astellas PharmaGastrointestinalGastroesophageal adenocarcinomaIntravenoushttps://www.astellas.com/en/ir/library/medical.html
gilteritinib (ASP2215)Astellas PharmaLeukemiaAcute myeloid leukemiaOralhttps://www.astellas.com/en/ir/library/medical.html
enfortumab vetodinAstellas PharmaGenitourinaryUrothelial cancerIntravenoushttps://www.astellas.com/en/ir/library/medical.html
ASG-16C3FAstellas PharmaGenitourinaryRenal cell carcinomaIntravenoushttps://www.astellas.com/en/ir/library/medical.html
selumetinibArray BioPharmaEndocrineDifferentiated Thyroid CancerOralhttp://www.arraybiopharma.com/product-pipeline/selumetinib
savolitinib/ volitinibAstraZenecaGenitourinaryPapillary renal cell carcinomahttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungBrain metastases in advanced EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungAdjuvant EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungfirst line advanced EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGenitourinaryProstate cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGynecologyFirst line BRCAm ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA adjuvant breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA metastatic breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGastrointestinalPancreatic cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
moxetumomab pasudotoxAstraZenecaLeukemiaHairy cell leukaemiaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
MEDI-573AstraZenecaBreastMetastatic breast cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalGastric cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalMetastatic pancreatic ductal carcinomaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalHepatocellular carcinomaIntravenoushttps://www.astrazeneca.com/our-science/pipeline.html
durvalumab + tremelimumabAstraZenecaLung3rd-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGenitourinary1st-line bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck2nd-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck1st-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaHead and NeckSquamous cell carcinoma of the head and neckIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaLungStage III NSCLCIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm
ImfinzidurvalumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaGenitourinaryAdvanced bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaGenitourinaryTreatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemo or who have disease progression within 12 mo. of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
cediranibAstraZenecaGynecologyRecurrent platinum resistant ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD6738AstraZenecaGastrointestinalGastric cancer, in combination with olaparibhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD5363AstraZenecaBreastBreast cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD1775AstraZenecaGynecologyOvarian cancer, in combination with chemotherapyhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLymphomaB-cell malignancyOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaHigh-risk relapsed/refractory chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line mantle cell lymphomaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
Radium-223 dichlorideBayerBreastbone metastasis in breast cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryCastration-resistant prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryhormone sensitive prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
GiotrifafatinibBoehringer IngelheimLungFirst‑line treatment of patients with common epidermal growth factor receptor (EGFR) mutations (del19/L858R) and advanced adenocarcinoma of the lungOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592558.htm
AliqopacopanlisibBayerLymphomaNon Hodgkin LymphomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomarelapsed follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm576098.htm
anetumab ravtansine BayerLungMalignant pleural mesotheliomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
xentuzumabBoehringer IngelheimBreastMetastatic breast cancer (oestrogen-receptor positive)https://www.inoncology.com/compounds/investigational/xentuzumab
xentuzumabBoehringer IngelheimGenitourinaryCastration-resistant prostate cancerhttps://www.inoncology.com/compounds/investigational/xentuzumab
VargatefnintedanibBoehringer IngelheimOtherUnresectable malignant pleural mesothelioma, in combination with pemetrexed/cisplatinOralhttps://www.inoncology.com/thoracic-malignancies-clinical-trials
VargatefnintedanibBoehringer IngelheimLungAdvanced or recurrent non‑small cell lung cancer patients after failure of first‑line therapy, in combination with pemetrexedOralhttps://www.inoncology.com/thoracic-malignancies-clinical-trials
VargatefnintedanibBoehringer IngelheimLungStage IIIB/IV or recurrent non‑small cell lung cancer (NSCLC) after failure of first‑line chemotherapy, in combination with docetaxelOralhttps://www.inoncology.com/thoracic-malignancies-clinical-trials
BI 836858Boehringer IngelheimLeukemiaAcute Myeloid Leukemiahttps://www.inoncology.com/our-compounds
BI 836858Boehringer IngelheimLeukemiaMyelodysplastic syndromehttps://www.inoncology.com/our-compounds
BI 836826Boehringer IngelheimLymphomaNon-Hodgkin lymphomahttps://www.inoncology.com/our-compounds
BI 836826Boehringer IngelheimLeukemiaChronic lymphocytic leukemiahttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimLungSquamous Cell Lung Cancer After at Least One Prior Platinum-Based ChemotherapyOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimLungNon-small cell lung cancer after failure of erlotinib or gefitinibOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimLungPatients with non-small cell lung cancer (NSCLC) who had failed at least one line of chemotherapy and erlotinib or gefitinib treatmentOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimHead and NeckRecurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum‑based therapyOralhttps://www.inoncology.com/compounds/afatinib/head-neck-cancer
GiotrifafatinibBoehringer IngelheimLungAdvanced NSCLC Harbouring HER2 Mutations, Previously Treated With ChemotherapyOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimGenitourinaryadvanced platinum-refractory urothelial cancerOralhttps://www.inoncology.com/compounds/afatinib/urothelial-carcinoma
OpdivonivolumabBristol-Myers SquibbGenitourinaryLocally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm
OpdivonivolumabBristol-Myers SquibbGastrointestinalmismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm
ThalomidthalidomideCelgeneMyelomaNewly diagnosed multiple myelomaOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
IstodaxromidepsinCelgeneLymphomaFirst-line peripheral T-cell lymphomaIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
IstodaxromidepsinCelgeneLymphomaCutaneous T-cell lymphomaIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Abraxanenab-paclitaxelCelgeneGastrointestinalPancreatic cancer, first-lineIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneOtherLower-risk myelodysplastic syndromeOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneOtherMyelodysplastic syndromeOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneLungAdvanced non-small cell lung cancerOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneBreastMetastatic breast cancerOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
Abraxanenab-paclitaxelCelgeneGastrointestinalAdjuvant therapy for pancreatic cancerIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
marizomibCelgeneNeurologicalGlioblastoma multiformehttps://www.celgene.com/content/uploads/product-pipeline.pdf
luspaterceptCelgeneOtherMyleodysplastic syndromeSubcutaneoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneOtherMyelodysplastic syndrome - deletion 5qOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaFirst-line diffuse large B-cell lymphoma (ABC-subtype)Oralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaRelapsed/refractory indolent lymphomaOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaFirst-line follicular lymphomaOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaMantle cell lymphoma (relapsed/refractory)Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm
IdhfaenasidenibCelgeneLeukemiarelapsed or refractory acute myeloid leukemia Oralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm
durvalumabCelgeneLeukemiaAcute myeloid leukemia (AML)Intravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
durvalumabCelgeneOtherMyleodysplastic syndromeIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
CC-486CelgeneLeukemiaPost-induction acute myeloid leukemia maintenanceIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (20-30% blasts)Intravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (>30% blasts)Intravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Vidazaazacitidine for injectionCelgeneOtherMyelodysplastic syndromesIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
RubracarucaparibClovis OncologyGynecologyDeleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapiesOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
MORAb-004EisaiMelanomaMelanomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalHepatocellular carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalBiliary tract cancerOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryFirst-line renal cell carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryin combination with everolimus, for advanced renal cell carcinoma following one prior anti-angiogenic therapyOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
farletuzumabEisaiGynecologyPlatinum-sensitive ovarian cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
HalaveneribulinEisaiGenitourinaryUnresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.Intravenous https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm
HalaveneribulinEisaiBreastBreast cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
amatuximabEisaiLungMesotheliomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
CyramzaramucirumabEli LillyGastrointestinalMetastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimenIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm
CyramzaramucirumabEli LillyGastrointestinalSecond-line treatment in patients with hepatocellular carcinoma and elevated Baseline alpha-fetoprotein (AFP) following first-line therapy with sorafenibIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalAdvanced gastric or gastroesophageal junction adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidineIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy, in combination with docetaxelIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm
CyramzaramucirumabEli LillyLungPreviously untreated patients with EGFR mutation-positive metastatic non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
ralimetinibEli LillyGynecologyOvarian cancerOralhttp://lillyoncologypipeline.com/clinical-phase/III
prexasertibEli LillyLungPatients with extensive-stage disease small cell lung cancer who have either platinum-sensitive or plantinum-resistant/refractory diseaseIntravenoushttp://lillyoncologypipeline.com/molecule/chk-1-inhibitor/trials
necitumumabEli LillyLungFirst-line stage IV squamous non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/molecule/egfr-antibody/trials
merestinibEli LillyGastrointestinalFirst-line advanced or metastatic biliary tract cancerOralhttp://lillyoncologypipeline.com/molecule/met-inhibitor/trials
LY3023414Eli LillyLungNon-small cell lung cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
LY3023414Eli LillyGenitourinaryProstate cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
galunisertibEli LillyGastrointestinalHepatocellular CarcinomaOralhttp://lillyoncologypipeline.com/molecule/tgf-beta-r-1-kinase-inhibitor/trials
emibetuzumabEli LillyLungNon-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
abemaciclibEli LillyGastrointestinalPancreatic cancerOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyLungStage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapyOralhttp://lillyoncologypipeline.com/clinical-phase/III
abemaciclibEli LillyLungSquamous non-small cell lung cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
abemaciclibEli LillyBreastPostmenopausal women with hormone-receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer, with anastrozole or fulvestrantOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyBreastwith Trastuzumab for Hormone-Receptor-Positive, HER2-Positive Locally Advanced or Metastatic Breast CancerOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyNeurologicalPatients with brain metastases secondary to hormone-receptor-positive breast cancer, non-small cell lung cancer, or melanomaOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
tepotinibEMD SeronoGastrointestinalHepatocellular cancerOralhttp://www.emdserono.com/en/research/Pipeline/research.html
tepotinibEMD SeronoLungNon-small cell lung cancerOralhttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGastrointestinalFirst line gastric cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGynecologyFirst line ovarian cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoHead and NeckLocally advanced head and neckIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoLungFirst line non-small cell lung cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoLungSecond line non-small cell lung cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGenitourinaryFirst line renal cell carcinomaIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGenitourinaryUrothelial cancer 1L1Intravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGenitourinaryLocally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
CometriqcabozantinibExelixisGastrointestinalHepatocellular cancer, second lineOralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib_Clinical_Trials-August_2017.pdf
CometriqcabozantinibExelixisSarcomaSoft tissue sarcomaOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisBreastBreast cancer patients with brain metastasesOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisBreastMetastatic, hormone-receptor positive breast cancer, with fulvestrantOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisLungNon-small cell lung cancer with molecular alterations in RET, ROS1, MET, AXL, or NTRK1Oralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisLungNon-small cell lung cancer: EGFR wild-typeOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGynecologyEndometrial cancerOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGynecologyHigh-grade uterine sarcomaOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisSarcomaRelapsed osteosarcoma or Ewing sarcomasOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisEndocrineDifferentiated thyroid cancerOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGenitourinaryMetastatic renal cell cancer. First-line, in combination with nivolumab +/- ipilimumabOralhttps://www.exelixis.com/lead-compounds/
ZelborafvemurafenibGenentechEndocrinePapillary thyroid cancer, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
CometriqcabozantinibExelixisGenitourinaryAdvanced renal cell carcinoma: previously untreated, intermediate or poor-risk patientsOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisBreastTriple negative breast cancerOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGenitourinaryAdvanced hepatocellular cancer, in combination with nivolumab +/- ipilimumabOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGastrointestinalPancreatic neuroendocrine and carcinoid tumorsOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGastrointestinalMetastatic gastrointestinal stromal tumorOralhttps://www.exelixis.com/lead-compounds/
ErivedgevismodegibGenentechOtherOperable basal cell carcinomaOralhttps://www.gene.com/medical-professionals/pipeline
RITUXAN HYCELArituximab and hyaluronidase humanGenentechLeukemiafollicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564235.htm
polatuzumab vedotinGenentechLymphomaNon-Hodgkin's lymphoma and diffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLeukemiaFront-line chronic lymphocytic leukemiaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaDiffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalGastric cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechBreastTriple-negative breast cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalProstate cancerOralhttps://www.gene.com/medical-professionals/pipeline
AvastinbevacizumabGenentechGynecologyRelapsed platinum-sensitive ovarian cancer Intravenoushttps://www.gene.com/medical-professionals/pipeline
TecentriqatezolizumabGenentechGenitourinaryFor locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chem or have disease progression within 12 mo's of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
tirabrutinibGilead SciencesLymphomaB-cell malignanciesOralhttp://www.gilead.com/research/pipeline
ZydeligidelalisibGilead SciencesLeukemiaRelapsed refractory chronic lymphocytic leukemia (CLL)Oralhttp://www.gilead.com/research/pipeline
entospletinibGilead SciencesLeukemiaAcute Myeloid LeukemiaOralhttp://www.gilead.com/research/pipeline
entospletinibGilead SciencesLeukemiaHematological MalignanciesOralhttp://www.gilead.com/research/pipeline
andecaliximabGilead SciencesGastrointestinalGastric CancerSubcutaneoushttp://www.gilead.com/research/pipeline
VenclextavenetoclaxHoffmann-La RocheLeukemiaFrontline chronic lymphocytic leukemia, in combination with GazyvaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaRealpsed/refractory chronic lymphocytic leukemia, in combination with rituximabOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiamyelodysplastic syndromes, first-line treatment, in combination with azacitidineOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheMyelomaRelapsed or refractory multiple myelomaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaFront-line diffuse large B-cell lymphomaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaRelapsed/refractory follicular lymphoma, in combination with rituximabOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaAcute myelogenous leukemia, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatment, in combination with PerjetaIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastSecond line HER2-positive metastatic breast cancer, in combination with TecentriqIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastThird line HER2-positive metastatic breast cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
taselisibHoffmann-La RocheBreastHER2-negative, hormone receptor-positive breast cancer, neoadjuvant treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
taselisibHoffmann-La RocheBreastHER2-negative, hormone receptor-positive metastatic breast cancerOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
polatuzumab vedotinHoffmann-La RocheLeukemiaHematological malignanciesIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
PerjetapertuzumabHoffmann-La RocheBreastEarly HER2-positive breast cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
GazyvaobinutuzumabHoffmann-La RocheLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, adjuvant treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
idasanutlinHoffmann-La RocheLeukemiaAcute myeloid leukemiaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
codrituzumabHoffmann-La RocheGastrointestinalMetastatic liver cancerhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumab + vemurafenibHoffmann-La RocheMelanomaBRAFv600 mutation-positive advanced melanoma, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheGastrointestinalThird-line advanced or metastatic colorectal cancer, in combination with TecentriqOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheBreastFirst line metastatic triple negative breast cancerOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGynecologyOvarian cancer, front-line treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous and squamous non-small cell lung cancer, PDL1-selected patientsIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell cancer, in combination with AvastinIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without AvastinIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungNon-small cell lung cancer, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line squamous non-small cell lung cancer, combination regimen with chemotherapyIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryMuscle-invasive bladder cancer, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryFirst-line metastatic urothelial carcinomaIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapyIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy and pemetrexedIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst line extensive-stage small cell lung cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell carcinoma, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreastMetastatic triple-negative breast cancer, first-line treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
YondelistrabectedinJanssenGynecologyRelapsed ovarian cancerIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia, in combination with obinutuzumabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia (young and fit), in combinaction with rituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaPatients with mantle cell lymphoma who have received at least one prior therapyOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm
ImbruvicaibrutinibJanssenLymphomaTreatment naive patients with mantle cell lymphoma, in combination with Bendamustine and RituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaRelapsed/refractory indolent non-Hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaNewly diagnosed non-germinal centre B-cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaMarginal zone lymphoma in patients who have received at least one prior therapyOralhttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with bortezomib, melphalan and prednisoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with lenalidomide and low-dose dexamethasoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-eligible patients, in combination with velcade, thalidomide and dexamethasomeIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
apalutamide + abiraterone acetateJanssenGenitourinaryMetastatic castration-resistant chemotherapy-naïve prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryNon-metastatic, castration-resistant prostate cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596796.htm
apalutamideJanssenGenitourinaryMetastatic hormone-sensitive prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryLocalized prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
ZytigaabirateroneJanssenGenitourinaryNewly Diagnosed Hormone Naïve Metastatic Prostate Cancer Oralhttp://www.janssen.com/research-and-development/product-pipeline
Vyxeosliposome-encapsulated combination of daunorubicin and cytarabine Jazz PharmaceuticalLeukemianewly diagnosed high risk AMLIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm
KeytrudapembrolizumabMerckGastrointestinalEsophogeal cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalrecurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
KeytrudapembrolizumabMerckGastrointestinalColorectal CancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalLiver cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyOvarian CancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckBreastBreast cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyRenal cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGenitourinaryProstate cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckNasopharyngeal cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckRecurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm
KeytrudapembrolizumabMerckMyelomaMultiple myelomaIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckLymphomaPrimary mediastinal primary B-cell lymphomaIntravenoushttp://www.merck.com/research/pipeline/home.html
OdomzosonidegibNovartisOtherlocally advanced basal cell carcinomaOralhttp://wayback.archive-it.org/7993/20170111231633/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
KisqaliribociclibNovartisBreastBreast cancer, in combination with Everolimus + Exemestane or in combination with fulvestrantOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
FarydakpanobinostatNovartisMyelomaMultiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agentOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htm
ArzerraofatumumabNovartisLeukemiaFor extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)Intravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
LCL161NovartisLeukemiaLeukemiahttps://pipeline.novartisoncology.com/ct/pipelineHome
LCL161NovartisMyelomaMultiple myelomahttps://pipeline.novartisoncology.com/ct/pipelineHome
EGF816NovartisLungNon-small cell lung cancerOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
capmatinibNovartisLungNon-small cell lung cancerOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
buparlisibNovartisGastrointestinalGastroesophageal junction cancerOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
buparlisibNovartisHead and NeckGlioblastoma multiformeOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
buparlisibNovartisHead and NeckHead and neck cancerOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
buparlisibNovartisBreastBreast cancerOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
alpelisibNovartisLungNon-small cell lung cancerOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
alpelisibNovartisHead and NeckHead and neck squamous cell carcinomaOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
alpelisibNovartisBreastAdvanced Breast Cancer That Has Progressed on or After Treatment With an Aromatase InhibitorOralhttp://www.trials.novartis.com/en/clinical-trials/us-oncology/oncology/solar/solar-1/overview/
talazoparibPfizerBreastGermline BRCA-mutated metastatic breast cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
SutentsunitinibPfizerGenitourinaryadjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585686.htm
IbrancepalbociclibPfizerBreastHigh-risk early breast cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastEarly breast cancer in adjuvant settingOralhttp://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastFor the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in combination with fulvestrantOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm
lorlatinibPfizerLungALK non-small cell lung cancer, first line and second lineOralhttp://www.pfizer.com/science/drug-product-pipeline
glasdegibPfizerLeukemiaAcute Myeloid Leukemia (AML)Oralhttp://www.pfizer.com/science/drug-product-pipeline
Mylotarggemtuzumab ozogamicinPfizerLeukemiaAcute Myeloid LeukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm
XtandienzalutamidePfizerGastrointestinalHepatocellular carcinomaOralhttp://www.pfizer.com/science/drug-product-pipeline
XtandienzalutamidePfizerGenitourinaryNon-metastatic castration-resistant prostate cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
XtandienzalutamidePfizerGenitourinaryMetastatic hormone sensitive prostate cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
dacomitinibPfizerLungFirst-line EGFR-mutant non-small cell lung cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
XalkoricrizotinibPfizerLungROS1-positive metastatic non-small cell lung cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm
BosulifbosutinibPfizerLeukemiaChronic myelogenous leukemia, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589856.htm
InlytaaxitinibPfizerGenitourinaryRenal cell carcinoma, adjuvant therapy in combination with pembroliumab Oralhttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerHead and NeckLocally Advanced Squamous Cell Carcinoma of the Head and NeckIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, second lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyOvarian cancer, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, third lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
neratinibPuma Biotechnology Inc.Breastfor the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm
cempilumab (SAR439684)SanofiSkinAdvanced cutaneous squamous cell carcinomaIntravenoushttps://en.sanofi.com/innovation/rd_portfolio/rd_portfolio.aspx
cempilumab (SAR439684)SanofiSkinAdvanced basal cell carcinomaIntravenoushttps://en.sanofi.com/innovation/rd_portfolio/rd_portfolio.aspx
cempilumab (SAR439684)SanofiLungNSCLC, first lineIntravenoushttps://en.sanofi.com/innovation/rd_portfolio/rd_portfolio.aspx
isatuximabSanofiLymphomaRelapsed refractory multiple myelomaIntravenoushttps://en.sanofi.com/innovation/rd_portfolio/rd_portfolio.aspx
tisotumab vetodinSeattle GeneticsGenitourinaryCervical cancerhttp://www.seattlegenetics.com/pipeline/tisotumab-vedotin
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline mature T-cell lymphomasIntravenoushttp://www.seattlegenetics.com/pipeline/brentuximab-vedotin
BavencioavelumabEMD SeronoOtherMerkel cell carcinoma, first lineIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaRelapsed non-Hodgkin lymphoma, in combination with nivolumabIntravenoushttp://www.seattlegenetics.com/pipeline/brentuximab-vedotin
BeleodaqbelinostatSpectrumLymphomaRelapsed or refractory peripheral T-cell lymphomaIntravenoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm
sapanisertib (TAK-228)TakedaBreastBreast cancerOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
IclusigponatinibTakedaLeukemiaPh+Acute lymphoblastic leukemia (ALL)Oralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaAmyloidosisOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
Adcetrisbrentuximab vedotinTakedaLymphomaHodgkin LymphomaIntravenoushttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
Adcetrisbrentuximab vedotinTakedaLymphomaMature T-cell lymphomaIntravenoushttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
Adcetrisbrentuximab vedotinTakedaLymphomaCutaneous T-Cell LymphomaIntravenoushttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
ZejulaniraparibTesaro, Inc.Gynecologymaintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm
UnituxindinutuximabUnited TherapeuticsNeurologicalHigh-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for pediatric patients who have achieved at least a partial response to prior first-line multiagent, multimodality therapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm437480.htm
GiotrifafatinibBoehringer IngelheimLungin Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the LungOralhttps://www.inoncology.com/compounds/afatinib/urothelial-carcinoma
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaindolent NHLIntravenoushttp://www.gilead.com/research/pipeline
YescartaAxicabtagene ciloleucel Kite PharmaceuticalsLymphomarelapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm581296.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm
CabometyxcabozantinibIpsen PharmaGastrointestinalHepatocellular carcinoma, second lineOralhttps://www.ipsen.com/research-development/pipeline/
E7777EisaiLymphomaPeripheral T-cell and Cutaneous T-Cell LymphomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
abemaciclibEli LillyBreastwith adjuvant therapy for High-Risk, Node-Positive, Early-Stage, Hormone-Receptor-Positive, HER 2-Negative Breast CancerOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyBreastPreviously Treated Hormone-Receptor-Positive, HER2-Negative, Metastatic Breast Cancer, with tamoxifenOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
XtandienzalutamidePfizerGenitourinaryNon-metastatic hormone sensitive, high risk, prostate cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
VerzenioabemaciclibEli LillyBreastin combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm578081.htm
cempilumab (SAR439684)SanofiGynecologyCervical cancerIntravenoushttps://en.sanofi.com/innovation/rd_portfolio/rd_portfolio.aspx
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaprimary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm
SpryceldasatinibBristol-Myers SquibbLeukemiapediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phaseOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584725.htm
BlincytoblinatumomabAmgenLeukemiaRelapsed/Refractory (R/R) Aggressive B-Cell NHLIntravenoushttp://www.amgenpipeline.com/pipeline/
IclusigponatinibTakedaLeukemiaChronic phase Chronic Myeloid Leukemia (CML)https://www.takeda.com/what-we-do/research-and-development/our-pipeline/
brigatinibTakedaLungALK+ Non-small cell lung cancerOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaMultiple myeloma, front lineOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
TAK-659TakedaLymphomaDiffuse large B-cell lymphomaOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
KTE-C19Gilead SciencesLymphomaMCLIntravenoushttp://www.gilead.com/research/pipeline
CalquenceacalabrutinibAstraZenecaLeukemiaMantle cell lymphoma, after at least one prior therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm
ABL001NovartisLeukemiaChronic Myeloid LeukemiaOralhttps://pipeline.novartisoncology.com/ct/pipelineHome
denintuzumab mafodotinSeattle GeneticsLymphomaDiffuse large B-cell lymphomaIntravenoushttp://www.seattlegenetics.com/pipeline/denintuzumab-mafodotin
ladiratuzumab vedotin (SGN-LIV1A)Seattle GeneticsBreastTriple negative breast cancerhttp://www.seattlegenetics.com/pipeline/sgn-liv1a
enfortumab vedotin Seattle GeneticsGenitourinarymetastatic urothelial cancer Intravenoushttp://www.seattlegenetics.com/pipeline/enfortumab-vedotin
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomapreviously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm601947.htm
OpdivonivolumabBristol-Myers SquibbMelanoma adjuvant treatment of patients with melanomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590004.htm
TecentriqatezolizumabHoffmann-La RocheBreastNeoadjuvant triple-negative breast cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
AvastinbevacizumabHoffmann-La RocheNeurologyGlioblastoma multiformeIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
GazyvaobinutuzumabGenentechLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreastAdjuvant HER2-positive breast cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590005.htm
PerjetapertuzumabGenentechGastrointestinalHER2-positive gastric cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
ZelborafvemurafenibGenentechMelanomaAdjuvant metastatic melanoma, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
Lutatheralutetium Lu 177 dotatateAdvanced Accelerator Applications USA, IncOtherreceptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm594105.htm
tazemetostatEisaiLymphomaNon-Hodgkin B cell Lymphomaoralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
SAR566658SanofiBreastTriple negative breast cancerhttps://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/common/docs/science-and-innovation/RD-all-projects-in-early-phases-or-late-phases-of-development.pdf
NinlaroixazomibTakedaMyelomaMultiple myeloma, relapsed/refractory, doublet regimenOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance therapy, with or without transplantOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
ZytigaabirateroneJanssenGenitourinaryin combination with prednisone for metastatic high-risk castration-sensitive prostate cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596015.htm
VerzenioabemaciclibEli LillyBreastin combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm598404.htm
ZytigaabirateroneJanssenGenitourinaryIn combination with prednisone and adrogen deprivation therapy (adt) for the treatment of patients with newly diagnosed high-risk mestastatic prostate cancer who may have received up to 3 months of prior ADTOralhttps://health-products.canada.ca/noc-ac/info.do?lang=en&no=20473
talazoparibPfizerGenitourinaryMetastatic castration-resistant prostate cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
xentuzumabBoehringer IngelheimLungNon small cell lung cancerhttps://www.inoncology.com/compounds/investigational/xentuzumab
VargatefnintedanibBoehringer IngelheimLungin combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapyOralhttps://www.inoncology.com/nintedanib
Somatuline PRFlanreotideIpsen PharmaGastrointestinalgastroenteropancreatic neuroendocrine tumors (GEP-NET)Subcutaneoushttps://www.ipsen.com/research-development/pipeline/
Onivydeirinotecan liposomeIpsen PharmaGastrointestinalPancreatic ductal adenocarcinomab (PDAC)Intravenoushttps://www.ipsen.com/research-development/pipeline/
Onivydeirinotecan liposomeIpsen PharmaLungSmall Cell Lung cancer (SCLC), second lineIntravenoushttps://www.ipsen.com/research-development/pipeline/
SomatulinelanreotideIpsen PharmaLungNeuroendocrine Tumours of LungSubcutaneoushttps://www.ipsen.com/research-development/pipeline/
KeytrudapembrolizumabMerckLungSmall Cell Lung cancer (SCLC)Intravenoushttp://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGastrointestinalPancreatic cancerOralhttp://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGenitourinaryProstate cancerOralhttp://www.merck.com/research/pipeline/home.html
isatuximabSanofiLymphomaNewly diagnosed multiple myelomaIntravenoushttps://en.sanofi.com/innovation/rd_portfolio/rd_portfolio.aspx
TasignanilotinibNovartisLeukemiapediatric patients with newly diagnosed or resistant/intolerant Ph+ CML in chronic phaseOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm602264.htm
BlincytoblinatumomabAmgenLeukemia B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm603171.htm

YesNo